A pancreatic islet cell inducer, culture medium, method for obtaining pancreatic beta cells and application thereof

By using astragalus saponin inducer to differentiate epithelial cells in a specific culture medium, the differentiation efficiency of pancreatic β cells was successfully improved, and the problem of low differentiation efficiency of pancreatic β cells was solved, and the significant improvement of diabetes symptoms when applied in vivo was achieved.

CN115948323BActive Publication Date: 2024-11-22NORTHEAST FORESTRY UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210109752.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-01-28
Publication Date
2024-11-22
Estimated Expiration
2042-01-28

AI Technical Summary

Technical Problem

In the prior art, the pancreatic β-cell differentiation efficiency is low, resulting in insufficient islet cell donors in the treatment of diabetes, making it difficult to effectively obtain functional islet cells.

Method used

Astragalus saponin is used as an inducer to differentiate epithelial cells in a specific culture medium to form pancreatic islet β cells, which improves the differentiation ratio and functionality.

Benefits of technology

The differentiation ratio of pancreatic β cells was significantly improved to 45%, and the blood sugar level and glucose tolerance of diabetic mice were significantly improved when used in vivo, with safe and effective activity, and enhanced the potential of pancreatic regeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115948323B_ABST
    Figure CN115948323B_ABST
Patent Text Reader

Abstract

The present invention discloses an islet cell inducer, a culture medium, a method for obtaining pancreatic β cells and their application, and belongs to the field of biomedical technology. In order to provide a method for drug development using small molecule compounds. The present invention provides a method for constructing epithelial organoids (EPOs), and after being treated with astragaloside substances, it can be found that astragaloside monomers in astragalus extracts can significantly promote EPOs to produce islet cells, which significantly promotes the expression of islet cell-related genes, especially insulin genes. The produced islet cells can secrete insulin in response to glucose stimulation, relieve the hyperglycemia symptoms of diabetic mice, and the produced insulin-secreting cells have the physiological function of mature β cells. The method can be used to prepare an artificial islet system for transplantation to treat diabetes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical technology, and in particular relates to a pancreatic islet cell inducer, a culture medium, a method for obtaining pancreatic islet β cells and applications thereof. Background Art

[0002] Diabetes mellitus (DM) is a chronic metabolic disease characterized by high blood sugar levels. The persistent high blood sugar levels it causes can cause widespread damage to the patient's heart, kidneys, and nerve tissues, leading to a variety of complications. Currently, diabetes has become an important public health issue worldwide, with a serious impact on economic development.

[0003] Islet transplantation is an effective method for treating diabetes, but it is limited by the severe shortage of pancreatic donors. How to obtain functional islet cells is one of the difficulties currently faced by cell replacement therapy for the treatment of diabetes. Among them, the successful construction of the pancreatic organoid culture system can be used to solve the problem of scarce organ transplant donor sources. Organoids refer to the use of the pluripotency of stem / progenitor cells to culture them in vitro, allowing them to continuously self-renew and self-organize to form tissues that are similar to the original organs in structure and function. Hans Clever and others successfully established pancreatic ductal organoids based on adult stem cells and organoid technology, and were able to differentiate them into insulin-positive cells towards pancreatic endocrine, but their differentiation efficiency is currently limited. Therefore, how to increase the differentiation efficiency of pancreatic β cells is an important issue that needs to be solved urgently.

[0004] Astragalus membranaceus (Fisch.) Bge.var.mongholicus (Bge.) Hsiao or Astragalus membranaceus (Fisch.) Bge. Modern pharmacological studies have confirmed that Astragalus membranaceus contains chemical components such as saponins, flavonoids and polysaccharides, as well as a variety of amino acids, folic acid and trace elements such as selenium, zinc and copper. It has the effects of enhancing the body's immune function, protecting the liver, diuresis, anti-aging, anti-stress, lowering blood pressure and a wide range of antibacterial effects. Studies have shown that astragalosides contained in Astragalus have the effects of improving insulin resistance, regulating lipid metabolism and glycogen metabolism, and alleviating diabetic nephropathy. In recent years, it has become an important direction for the treatment of diabetes. Summary of the invention

[0005] The purpose of the present invention is to provide a method for obtaining pancreatic islet cells in vitro using astragaloside small molecules and epithelial cells. Another purpose of the present invention is to provide a method for producing a large number of pancreatic islet cells, especially β cells, with physiological functions, for preparing artificial pancreatic islets and for in vivo application to treat diabetes.

[0006] The invention provides an inducer of pancreatic islet cells, wherein the effective component of the inducer is astragaloside.

[0007] It is further defined that the pancreatic islet cells are pancreatic α cells, pancreatic β cells, pancreatic δ cells or pancreatic pp cells.

[0008] It is further defined that the effective inducer is any one or more of astragaloside I to VIII, isoastragaloside I, II and IV, acetylastragaloside, cyclosieversioside E, F and G, agroastragaloside I to IV and soybean saponin I, and any one or more of their derivatives.

[0009] It is further defined that the active ingredient of the inducer is isoastragaloside I.

[0010] The invention provides a culture medium for producing pancreatic islet cells, wherein the culture medium contains astragaloside.

[0011] Further defined, the culture medium further comprises an organoid proliferation medium.

[0012] It is further defined that the pancreatic islet cells are pancreatic α cells, pancreatic β cells, pancreatic δ cells or pancreatic pp cells.

[0013] Further defined, the culture medium contains isoastragaloside I.

[0014] It is further defined that the concentration of the astragaloside is 0.1-8 μM.

[0015] The invention provides a method for obtaining pancreatic islet beta cells, wherein epithelial cells are cultured in a culture medium containing astragaloside to differentiate and obtain pancreatic islet beta cells.

[0016] It is further defined that the epithelial cells are liver, gallbladder, pancreas, stomach and intestinal epithelial cells of humans or mammals.

[0017] It is further defined that the active ingredients of the astragalosides system are any one or more of astragalosides I to VIII, isoastragalosides I, II and IV, acetylastragaloside, cyclosieversioside E, F and G, agroastragaloside I to IV and soybean saponin I, and any one or more of their derivatives.

[0018] It is further defined that the active ingredient of the astragalosaponin system is isoastragaloside I.

[0019] It is further defined that the concentration of the astragaloside is 0.1-8 μM.

[0020] The present invention provides pancreatic islet β cells obtained by the above method for obtaining pancreatic islet β cells.

[0021] The present invention provides the use of the pancreatic islet β cells in preparing a cell medicine for treating diabetes.

[0022] It is further defined that the dosage form of the cell medicine includes injection.

[0023] It is further defined that the cell medicine contains an extracellular matrix and a pharmaceutical carrier that are compatible with cells.

[0024] It is further defined that the pharmaceutical carrier is a nanomaterial or a microfluid. It is further defined that the culture medium also contains an organoid proliferation culture medium or a basal culture medium.

[0025] The basic culture medium is Advanced DMEM / F12, and the basic supplementary components for cell culture include glutamine and antibiotics, wherein the concentration of 1×glutamine in Advanced DMEM / F12 is 2 mM, and the antibiotic is penicillin-streptomycin, and the concentrations are 100 U / mL penicillin and 0.1 mg / mL streptomycin.

[0026] The organoid proliferation medium is based on the basal medium and contains at least one selected from Wnt agonists, transforming growth factor-β (TGF-β) inhibitors, epidermal growth factor EGF, and fibroblast growth factor (FGF).

[0027] The Wnt agonist may be selected from one or more of the following free-standing molecules: Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, Wnt16, and R-spondin1.

[0028] BMP signaling pathway inhibitors include Noggin, Dorsomorphin, LDN189, DMH-1, and combinations thereof, preferably Noggin.

[0029] FGF includes: FGF1, FGF2, FGF3, FGF4, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, FGF23 and combinations thereof, preferably FGF10.

[0030] Preferably, the culture medium contains an extracellular matrix.

[0031] The extracellular matrix (ECM) contains various polysaccharides, water, elastin, and glycoproteins, such as collagen, entactin, fibronectin, and laminin.

[0032] It is further defined that the pancreatic islet cells are pancreatic α cells, pancreatic β cells, pancreatic δ cells or pancreatic pp cells.

[0033] The present invention provides a method for obtaining pancreatic islet beta cells in vitro, wherein epithelial cells are differentiated in a system containing astragaloside to obtain pancreatic islet beta cells.

[0034] It is further defined that the epithelial cells are liver, gallbladder, pancreas, stomach, and intestinal epithelial cells of humans or mammals.

[0035] Epithelial starting cells are seeded in an extracellular matrix and cultured in EM medium at 37°C, 5% CO2 incubator for 5 days to form organoids, which can be serially subcultured and cryopreserved.

[0036] It is further defined that the astragalosides are any one or more of astragalosides Ⅰ to Ⅰ, isoastragalosides Ⅰ, Ⅱ and Ⅳ, acetylastragaloside, cyclosieversioside E, F and G, agroastragaloside Ⅰ to Ⅳ and soybean saponin Ⅰ, and any one or more of their derivatives.

[0037] It is further defined that the concentration of the astragaloside is 0.1-8 μM.

[0038] The present invention provides the use of the pancreatic islet β cells obtained by the above method in preparing a cell medicine for treating diabetes in vitro.

[0039] The present invention provides application of the method for preparing pancreatic β cells in preparing a medicament for inducing pancreatic β cells in animals.

[0040] It is further defined that the dosage form of the drug includes injection.

[0041] It is further defined that the injection comprises sodium chloride, magnesium chloride, sodium calcium edetate and water for injection.

[0042] It is further defined that the cell medicine further contains a pharmaceutical carrier that is compatible with cells.

[0043] Further defined, the drug also contains medically acceptable excipients, including adhesives, fillers, disintegrants, lubricants, antioxidants, flavoring agents, solubilizers, emulsifiers, solubilizers, osmotic pressure regulators, colorants. Cellular and physiologically acceptable excipients or diluents include lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, ethylparaben, propylparaben, talc, magnesium stearate and mineral oil.

[0044] Further defined, the drug also contains a pharmaceutical carrier, the pharmaceutical carrier includes an extracellular matrix, a nanomaterial and a microfluid, the extracellular matrix is ​​a variety of polysaccharides, water, elastin, and glycoproteins, the glycoproteins are collagen, entactin, fibronectin, laminin, the nanomaterials are mesoporous silica, liposomes, polylactic-co-glycolic acid (PLGA), albumin, exosomes.

[0045] The invention provides an inducer for inducing epithelial cells, wherein the inducer contains astragaloside.

[0046] The invention provides a method for inducing epithelial cell differentiation, which involves differentiating the epithelial cells in a system containing astragaloside.

[0047] It is further defined that the epithelial cells are liver, gallbladder, pancreas, stomach, and intestinal epithelial cells of humans or mammals.

[0048] It is further defined that the astragalosides are any one or more of astragalosides Ⅰ to Ⅰ, isoastragalosides Ⅰ, Ⅱ and Ⅳ, acetylastragaloside, cyclosieversioside E, F and G, agroastragaloside Ⅰ to Ⅳ and soybean saponin Ⅰ, and any one or more of their derivatives.

[0049] It is further defined that the concentration of the astragaloside is 0.1-8 μM.

[0050] A chemical small molecule composition comprising astragaloside, which is a pharmaceutical composition, further comprising: a pharmaceutically acceptable carrier or excipient; preferably, the carrier or excipient comprises one or more selected from the following groups: water, saline, phosphate buffer or other aqueous solvents; DMSO, glycerol and ethanol or other organic solvents; microspheres, liposomes, microemulsions or polymer surfactants; colloid drug delivery systems or polymer drug delivery systems; preservatives, antioxidants, flavoring agents, aromatics, cosolvents, emulsifiers, pH buffer substances, adhesives, fillers, lubricants or other pharmaceutical excipients; or pharmaceutical dosage forms that can be prepared from the chemical small molecule composition include: solid dosage forms, including powders, granules, tablets, pills, capsules, sustained-release agents, controlled-release agents, or other solid dosage forms; liquid dosage forms, including injections, infusions, suspensions, or other liquid dosage forms; gaseous dosage forms; or semisolid dosage forms.

[0051] The invention includes the use of astragaloside for preparing preparations, reagents or culture media for islet cells; or for preparing drugs / drug precursors / drug compositions for inducing in situ epithelial cells to differentiate into islet cells in vivo, and for in situ differentiating pancreatic duct cells to promote the regeneration of pancreatic β cells, lower blood sugar, and achieve the treatment of diabetes-related diseases (such as diabetic foot, diabetic nephropathy, poor skin healing caused by diabetes, diabetic cardiovascular disease, etc.); or for preparing islet cells for inducing epithelial cell differentiation in vitro.

[0052] The use of chemical small molecules including astragaloside can be used to prepare drug boxes or test kits for inducing pancreatic islet cells in vivo and in vitro, or based on the small molecules, pharmaceutically acceptable carriers or excipients are added to induce in situ or gastrointestinal cells to directly transform into pancreatic islet cells in vivo, and their in situ differentiation effect can reduce or reduce tissue / organ lesions, and develop or prepare drugs or prodrugs / drug compositions for treating clinical diabetes (such as diabetic foot, diabetic nephropathy, poor skin healing caused by diabetes, diabetic cardiovascular disease, etc.); or differentiation culture media or test kits for inducing epithelial cells to directly differentiate into pancreatic islet cells prepared by adding carriers or excipients such as organic solvents / physiological saline / buffer / cell basal culture media.

[0053] A medicine box or a test kit comprising astragaloside, wherein the epithelial cells include but are not limited to: human or mammalian gastrointestinal epithelial cells; including but not limited to: human: extrahepatic and intrahepatic bile duct epithelial cells, pancreatic duct epithelial cells, gastric epithelial cells, small intestine and large intestine epithelial cells or epithelial cells of other tissues or organs of the human body; more preferably human pancreatic duct and bile duct epithelial cells.

[0054] Beneficial effects: The present invention discloses astragalosides and methods for inducing the production of islet cells from intrahepatic bile duct epithelium, extrahepatic bile duct epithelium, pancreatic duct epithelium, gastric epithelium, and intestinal epithelial cells. By constructing epithelial organoids (EPOs), after treatment with astragalosides, it can be found that isoastragalosides I in astragalus extract can significantly promote the differentiation of EPOs, which significantly promotes the expression of islet cell-related genes. In this differentiation-promoting process, the up-regulated expression of pancreatic endocrine progenitor cell marker gene ngn3 was observed. The differentiated cells can respond to glucose stimulation, improve blood sugar and glucose tolerance in diabetic mice, and have the physiological functions of mature β cells.

[0055] Isosaconoside I can not only significantly promote the expression of insulin-related genes Insulin 1 and Insulin 2 in mouse pancreatic ductal organoids (mPDOs), but also the β-cell differentiation rate can reach 45%, which is 30 times higher than the 1.5% differentiation efficiency reported in the literature (Loomans CJM, et al., Stem Cell Reports 2018; 10: 712-724). The secretion of synthetic insulin marker C-peptide can be detected in differentiated mPDOs under glucose stimulation, proving that it has the same physiological response to glucose stimulation as mature β cells. Adding isosaconoside I at a concentration of less than 8μmol / L has no effect on organoid growth and cell activity, proving that it is a safe, effective, and active astragalus molecule with great application potential. At the same time, the results of the in vivo transplantation of human extrahepatic bile duct organoids (hBDOs) pretreated with isoastragaloside I have shown that it has in vivo active effects such as alleviating hyperglycemia symptoms in diabetic mice and improving glucose tolerance. Isoastragaloside I alone added to the organoid culture medium has a significant effect on promoting β-cell differentiation, suggesting that it may have a more comprehensive effect in vivo, such as promoting pancreatic regeneration. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1 For the establishment of mouse pancreatic ductal organoids (mPDOs). Figure 1 A is the pattern diagram of mPDOs; Figure 1 B is the cell status diagram of mPDOs cultured on the 5th day, 10th day, 14th day, 1st generation, and 10th generation;

[0057] Figure 2 A single molecule screening of astragaloside was performed using the PDOs model prepared using RIP-cre; Rosa26-mTmG hybrid mice. Figure 2 A is a schematic diagram of the genetic background of RIP-cre; Rosa26-mTmG animals; Figure 2 B is the cell fluorescence image of RIP-cre; Rosa26-mTmGPDOs after adding Astragalus extract; Figure 2 E is the quantitative fluorescence intensity of RIP-cre; Rosa26-mTmG PDOs after adding Astragalus extract; Figure 2 F is the Q-PCR graph of RIP-cre; Rosa26-mTmG PDOs after adding Astragalus extract;

[0058] Figure 3 The structure of isoastragaloside I and its safety for mPDOs. Figure 3A is the chemical structural formula of isoastragaloside I; Figure 3 B is a CCK8 graph for detecting the activity of mPDOs after adding different concentrations of isoastragaloside I;

[0059] Figure 4 Isosaconoside I can effectively promote the differentiation of mPDOs into pancreatic cells in vitro. Figure 4 A is the Q-PCR graph after culturing mPDOs with isoastragaloside I for 14 days; Figure 4 B is the immunostaining image of mPDOs cultured for 14 days after adding isoastragaloside I;

[0060] Figure 5 Isosaconoside I can effectively promote the differentiation of mPDOs into functional β cells in vitro. Figure 5 A and B are flow cytometry results of C-peptide after adding isoastragaloside I to culture mPDOs for 14 days. + Cell ratio; Figure 5 C: mPDOs were cultured with isoastragaloside I for 14 days and then stimulated with glucose, and C-peptide secretion was detected by ELISA;

[0061] Figure 6 Establishment of human hepatobiliary and pancreatic ductal organoids. Figure 6 A is a schematic diagram of the establishment of human liver, gallbladder, and pancreatic ductal organoids (hLDOs; hBDOs; hPDOs); Figure 6 B shows the cell status diagram of hBDOs cultured on the 3rd day, 7th day, 14th day, 5th generation, and 20th generation;

[0062] Figure 7 To treat diabetes by in vivo transplantation of hBDOs differentiated by isoastragaloside I. Figure 7 A is a graph showing changes in blood glucose after transplantation of hBDOs treated with isoastragaloside I into the renal cysts of STZ-induced diabetic mice; Figure 7 B and C show the changes in glucose tolerance in mice after transplantation of hBDOs treated with isoastragaloside I; Figure 7 D is the change of Insulin level in mouse serum. DETAILED DESCRIPTION

[0063] "EM medium" refers to a basic cell culture medium supplemented with Wnt signaling activators and TGFβ receptor inhibitors, as well as growth factors for promoting organoid formation, for example, D / F12 medium, DMEM medium or MEM medium, which contains 2% B27, 1% Glutamax, 1% N2 supplement, A8301, noggin, niacinamide and N-acetyl-L-cysteine ​​and is supplemented with cytokines such as EGF, R-spondin 1, FGF10, PGE2, Gastrin, etc.

[0064] "EPOs" refers to organoids derived from hepatobiliary and pancreatic gastrointestinal epithelial cell cultures; "mPDOs" refers to organoids derived from mouse pancreatic ductal cell cultures; "hBDOs" refers to organoids derived from human bile duct epithelial cell cultures; the above organoids may be primary cultures (e.g., cultures that have not been subcultured), or may be secondary or subsequent subcultures (e.g., cell populations that have been subcultured or subcultured one or more times).

[0065] "Conversion" refers to the conversion of pancreatic ductal cells from a unipotent to a pluripotent state.

[0066] "Marker" refers to a biomarker that can mark a system, organ, tissue, cell, or subcellular structure, or a biochemical indicator of a functional change or a possible change. In this article, the pancreatic endocrine cells, the β cell marker is insulin, the α cell marker is glucagon, the δ cell marker is somatostatin, and the pancreatic PP cell marker is pancreatic polypeptide.

[0067] "Pancreatic somatic cells" refer to pancreatic cell types present in pancreatic tissue, including pancreatic ducts, islets, and acinar cells. In a preferred embodiment, they are pancreatic duct cells. The cells can be obtained from a donor that can be transplanted from a mammal, such as a human, monkey, pig, etc.

[0068] Healthy Nu / Nu mice aged 7-8 weeks were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd., and RIP-cre; Rosa26-mTmG hybrid mice were purchased from The Jackson Laboratory. The breeding and use of experimental animals were approved by the Animal Ethics Committee of Northeast Forestry University. They were kept in accordance with the requirements of the SPF-level experimental animal room, with a 12-h light / dark cycle at room temperature, and were fed food and water regularly by facility staff.

[0069] Various types of astragalosides are purchased as standard products, and can also be extracted and separated using astragalosides active ingredient extraction techniques including water extraction, alcohol extraction, microwave extraction, microwave-assisted purification, microwave-assisted water extraction, pre-column derivatization, resin adsorption, supercritical CO2 extraction, ultrafiltration, etc.

[0070] Pancreatic progenitor cells, embryonic stem cells, neural progenitor cells, bone marrow mesenchymal stem cells, liver stem cells, umbilical cord blood cells, blood-derived endometrial stem cells, and dental pulp mesenchymal stem cells can all be induced to differentiate into pancreatic β cells in vitro.

[0071] According to different methods of inducing islet-like cells in vitro, the inducers can be roughly divided into three categories: 1) cytokines, such as EGF, bFGF, Extendin-4, etc.; 2) organic compounds, such as niacinamide, retinoic acid, DMSO, β-mercaptoethanol, etc.; 3) conditioned culture medium, such as rat regenerated pancreatic extract, etc.

[0072] In the in vitro induction schemes for pancreatic islet-like cells, there are distinctions based on the presence or absence of serum induction, and also based on the induction steps, among which the typical representatives are the "one-step method" to the "four-step method".

[0073] The "one-step induction method" mainly uses an in vitro induction medium with the same ingredients to induce differentiation into islet-like cells. For example, serum-free medium is used to induce mesenchymal stem cells into islet-like cells in vitro. 0.6% glucose, 100 μg / mL transferrin, 20nM progesterone, 25μg / mL insulin, 30nM selenium chloride, 60μM diamine, 2mM glutamine, 3mM sodium bicarbonate, 5mM HEPES buffer, 2μg / mL heparin, 20ng / mL EGF, 20ng / mL bFGF, 20ng / mL HGF, 10mM nicotinamide and 100ng / mL activin A are added to the D / F medium, and the cells induced in vitro after 14 days.

[0074] The "two-step induction method" means that the entire in vitro induction process is divided into two steps, such as in vitro induction of rat bone marrow mesenchymal stem cell-directed islet-like cell differentiation, wherein in the first step, 10mmol / L niacinamide and 1mmol / L β-mercaptoethanol, 20% FBS are added, and the induction is carried out in low-glucose DMEM medium for 24 hours, and in the second step, 10mmol / L niacinamide and 1mmol / L β-mercaptoethanol are added, and the induction is continuously carried out in serum-free high-DMEM medium for 10 hours, and finally the in vitro induction is completed.

[0075] In the "three-step induction method", 1% BSA, 1% PSA, activin A, ITS-X, sodium butyrate and β-mercaptoethanol are added to the D / F medium in the first step; 1% BSA, 1% PSA, ITS-X and taurine are added to the D / F medium in the second step; 1% BSA, 1% PSA, ITS-X, niacinamide, taurine and GLP-1 are added to the D / F medium in the third step. After these three steps of in vitro induction, insulin-like secreting cells are finally formed.

[0076] In the "four-step induction method", 0.2% FBS, 20ng / mL Wnt3A and 100ng / mL Activin-A are added for 24h, and then 0.3% FBS and 100ng / mL Activin-A are added for 24h; in the second step, 2% FBS and 50ng / mL FGF are added for continuous induction for 3 days; in the third step, 0.25μmol / L SANT-1, 2μmol retinoic acid, 100ng / mL Noggin and 1% B27 are added for continuous induction for 4 days; in the fourth step, 100ng / mL Noggin, 50nmol / LTPB, 1μmol / L ALK5 inhibitor are added for continuous induction for 4-5 days, and finally in vitro induction can form islet-like cells. In summary, for the in vitro induction of mesenchymal stem cells into pancreatic islet-like cells, there are many methods and many types of inducers that can be used. There is no unified standard for in vitro induction internationally, nor is there a universally recognized inducer and unified induction steps.

[0077] Continuous stimulation of NOD mice with human glucagon-like peptide 1 (GLP-1) can promote the differentiation and proliferation of pancreatic ductal epithelial cells.

[0078] Low-sugar DMEM / F12 medium is used. D / F12 can keep the pH of the culture medium stable, which is more conducive to the growth of epithelial cells than 1640 medium. Glucose is the most important factor in stimulating gene expression in pancreatic β cells, but its high concentration can affect insulin expression and affect the differentiation of pancreatic β cells.

[0079] Growth factors can not only accelerate cell division and enhance activity, but also promote their transdifferentiation into insulin-secreting cells. For example, FGF7 is a mitogen that not only promotes the growth and rapid reproduction of pancreatic ductal epithelial cells, but also has the function of promoting their transformation into pancreatic stem cells. DMEM / F12 culture medium combined with nicotinamide can promote the in vitro growth of rat and pig ductal cells.

[0080] Commercially available ECMs include extracellular matrix proteins (manufactured by Invitrogen), basement membrane preparations derived from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells (such as Matrigel (manufactured by BD Biosciences)), etc. ProNectin (Sigma Z378666) and other synthetic ECMs can be used. In addition, a mixture of natural ECM and synthetic ECM can be used. Hydrogels, hydrogels for three-dimensional organoid culture include commercially available hydrogels for preparing organoids selected from Yeasen polypeptide hydrogels and the like.

[0081] Example 1. A culture medium for culturing pancreatic islet cells

[0082] Human expansion medium (hEM) formula: 1% Penicillin-Streptomycin Solution (HyClone; SV30010), 1% glutamine supplement (gibco; 35050-061), 2% B27 without vitamin A (Thermo; 12587010), 50ng / mL EGF (MCE; HY-P7067), 50ng / mL FGF10 (PeproTech; 100-26-25), 25ng / mL NOGGIN (PeproTech; 120-10C-20), 1% N2 (Thermo; 17502001), 10nM Gastrin (SIGMA; G9145), 3μM PGE2 (SIGMA; P0409), 5μM A83-01 (MCE; HY-10432), 1mol / L Nicotinamide (Sigma; N0636), 1 mol / L N-acetyl-L-cysteine ​​(Sigma; A9165), 100 ng / mL R-Spondin-1 (R&D; 7150-RS), add D / F12 to 40 mL (HyClone; SH30022.01);

[0083] Mouse expansion medium (mEM) formula: 1% Penicillin-Streptomycin Solution (HyClone; SV30010), 1% glutamine supplement (gibco; 35050-061), 2% B27 without vitamin A (Thermo; 12587010), 50ng / mL EGF (MCE; HY-P7067), 50ng / mL FGF10 (PeproTech; 100-26-25), 25ng / mL NOGGIN (PeproTech; 120-10C-20), 1mol / L Nicotinamide (Sigma; N0636), 1mol / L N-acetyl-L-cysteine ​​(Sigma; A9165), 100ng / mL R-Spondin-1 (R&D; 7150-RS), supplemented with D / F12 to 40 mL (HyClone; SH30022.01); prepare in the above EM medium any one or more of astragaloside I to I, isoastragaloside I, II and IV, acetylastragaloside, cyclosieversioside E, F and G, agroastragaloside I to IV and soybean saponin I with a final concentration of 0.5, 1, 2, 4, 8 μM and any one or more of their derivatives.

[0084] Example 2. A method for obtaining pancreatic β cells

[0085] The method for obtaining pancreatic β cells in vitro is as follows:

[0086] 1. Cultivation of Mouse Pancreatic Ductal Organoids

[0087] Mouse pancreatic ductal epithelial cells were initially seeded in extracellular matrix and cultured in mEM medium at 37°C, 5% CO2 incubator for 5 days to form organoids.

[0088] (1) Primary culture of mouse pancreatic ductal organoids (mPDOs): Use a mechanical method to directly dissect the mouse extrahepatic bile duct (PD) under a dissecting microscope, place the obtained PD in an EP tube containing collagenase IV, and cut it into pieces using surgical scissors. Digest at 37°C for 20 minutes, take out every 5 minutes, and repeatedly blow with a 1mL pipette tip to terminate the digestion on ice. Centrifuge and discard the supernatant, wash three times with sterile PBS, resuspend the digested cells in Matrigel (Corning, 54234), drop them into a 24-well plate and let stand at 37°C for 5 minutes to allow the matrix gel to solidify. Add 800 μL of mouse expansion medium (mEM) to each well for culture. For specific operation steps, see Figure 1 A.

[0089] The cells obtained by the above method were cultured in Matrigel, and the formation of obvious organoid structures could be observed around the 5th day. As the culture time prolonged, around the 10th day, the cell density of mPDOs increased significantly. After about 14 days of culture, the cells grew to fill the Matrigel and could be subcultured and cryopreserved.

[0090] (2) Subculture of mouse pancreatic ductal organoids (mPDOs): Use pre-cooled high-glucose DMEM medium (HyClone; SH30022.01) to break up the organoids and resuspend them. After centrifugation, remove the supernatant, and use Matrigel and mEM to subculture the precipitate. Depending on the cell density, subculture once every 7 to 8 days at a ratio of 1:3-1:5.

[0091] (3) Cryopreservation of mouse pancreatic ductal organoids (mPDOs): Use pre-cooled high-glucose DMEM medium (HyClone; SH30022.01) to break up the organoids and resuspend them. After centrifugation to remove the supernatant, add 1 mL of pre-cooled organoid freezing solution and transfer the resuspended organoids into cell cryopreservation tubes. After placing the cryopreservation tubes in a cryopreservation box, move them into a -80°C refrigerator overnight. The next day, transfer the cryopreservation tubes into liquid nitrogen for storage.

[0092] The mPDOs obtained in this study can be passaged for a long time and have stable proliferation and passage ability. Even when passaged to the 10th generation, they can still maintain a good cell state. Figure 1 B. The structural formula of isoastragaloside I is shown in Figure 3 As shown in A.

[0093] The human monotubular epithelial cells were cultured in EM culture medium containing any one or more of astragaloside I-VIII, isoastragaloside I, II and IV, acetylastragaloside, cyclosieversioside E, F and G, agroastragaloside I-IV and soybean saponin I at final concentrations of 0.1, 0.5, 1, 2, 4, and 8 μM, respectively, and any one or more of their derivatives. The induction time was 14 days, and finally pancreatic islet cells were obtained.

[0094] The following experiments are used to verify the experimental results:

[0095] (1) Fluorescence intensity measurement: mPDOs prepared from RIP-cre; Rosa26-mTmG hybrid mice were measured at 1×10 3 The density of 1000 cells / mL was plated in a 96-well plate. RIP-cre; Rosa26-mTmG PDOs were cultured in mEM containing different concentrations of Astragalus extract for 14 days. The culture plate was placed in a TECAN microplate reader to measure the EGFP fluorescence intensity. The Ex / Emλ of EGFP was 488 / 507. RIP-cre; Rosa26-mTmG PDOs without Astragalus extract were used as controls to calculate the percentage of fluorescence intensity.

[0096] Results: Based on the principle of cell lineage tracing, mPDOs expressing GFP driven by the insulin promoter were prepared using RIP-cre; Rosa26-mTmG hybrid mice, and a mouse insulin expression fluorescent reporter system was established ( Figure 2 A), when the insulin gene is not expressed in the cells, the cells express red fluorescent protein. When the added molecules promote the differentiation of mPDOs into β cells (insulin-secreting cells), the differentiated cells can specifically express green fluorescence. According to the fluorescence changes of RIP-cre-mTmG PDOs ( Figure 2 EF), isoastragalosidone I was screened out from different astragalosidone monomers.

[0097] (2) Cell activity detection: mPDOs were digested into single cells using trypsin and resuspended in pre-cooled Matreigel at a concentration of 1×10 3 / well were plated in a 96-well plate, and mEM medium containing 0, 0.5, 1, 2, 4, 8, and 10 μM isoastragaloside I was added. CCK8 detection was performed after 14 days of culture. On the day of detection, the medium in the 96-well plate was discarded, and the CellCounting Kit-8 reagent (bimake; B34302) and D / F12 were mixed at a ratio of 1:9 and added to the 96-well plate, 100 μL per well, and the absorbance was detected at 450 nm after incubation at 37°C in the dark for 4 hours.

[0098] Results: In order to determine the safe concentration of isoastragaloside I for inducing differentiation of mPDOs, the effect of isoastragaloside I on cell activity was detected using CCK8. It was found that the drug concentration of 1-8 μmol / L had no effect on cell growth, while when the concentration reached 10 μmol / L, isoastragaloside I could significantly inhibit cell proliferation activity, indicating that the 1 μmol / L concentration used above is very safe ( Figure 3 B).

[0099] (3) Fluorescence quantitative PCR: After adding isoastragaloside I to mPDOs for 14 days, the mPDOs were collected by centrifugation and lysed in TRIZOL to extract total RNA. Primerscript was used RT Total RNA was converted to cDNA using the master kit (Vazyme, R323-01). The reaction system and conditions were referred to the instructions for ChamQ Universal SYBR qPCR Master Mix (Vazyme, Q711-02) (primers are shown in Table 1), and the Roche Light Cycle 480 fluorescence quantitative PCR instrument was used for detection. The analysis was performed using the Light Cycler 480 software analysis module, and the Ct value was calculated using Abs Quant / 2nd Derivative Max, and 2 -ΔΔCt The relative mRNA expression was calculated by the method.

[0100] Table 1 Mouse primer sequences

[0101]

[0102] (4) Immunostaining: After culturing mPDOs in mEM containing 1 μM isoastragaloside I (MCE, HY-N0887) for 14 days, the mPDOs were washed with PBS, fixed with 4% PFA for 20 min, and washed three times with cold PBS. The cell suspension was added to a glass slide and dried at 37°C until the organoids were fixed on the slide. 0.3% Triton X-100 was used for perforation at 37°C for 1 h, antigen retrieval solution (Biyuntian, P0090) was used for repair at room temperature for 10 min, 10% horse serum was used for blocking at 37°C for 1 h, primary antibody was added for incubation at 4°C overnight, secondary antibody was used for incubation at room temperature for 2 h, Hochest 33342 (1:1000) was used for staining for 15 min, and anti-fluorescence quenching was used for sealing (Biyuntian, P0126). Fluorescence photography was performed using the high-resolution live cell imaging system DeltaVision. Antibody catalog numbers and concentrations used are shown in Table 2.

[0103] Table 2 Antibody sources and concentrations used

[0104]

[0105] Results: The gene and protein expressions of pancreatic endocrine markers were significantly upregulated in hBDOs after differentiation.

[0106] Results: Isosaconoside I can effectively promote the differentiation of mPDOs into pancreatic cells in vitro, and the gene and protein expressions of pancreatic endocrine markers in differentiated mPDOs are significantly upregulated ( Figure 4 AB).

[0107] (5) Flow cytometry: The differentiated mPDOs were digested into single cells using trypsin, fixed with 4% PFA on ice for 15 min, washed with PBS, punched with 0.1% TritonX-100 at room temperature for 10 min, washed with PBS, blocked with 5% BSA at room temperature for 15 min, left at room temperature for 15 min, and incubated on ice for 40 min with primary antibody (C-peptide, 1:200) diluted in 3% BSA. The control group was added with isotype antibody dilution, washed with PBS, and incubated on ice in the dark for 30 min with secondary antibody (donkey anti-rabbit 488, 1:100) diluted in 3% BSA. After washing with PBS, 500 μL of the cells were resuspended and tested.

[0108] (6) Glucose stimulates C-peptide secretion: After culturing mPDOs in mEM containing 1 μM isoastragaloside I for 14 days, the organoids were resuspended in sugar-free Krebs solution, washed 2 to 3 times, placed in a low-adsorption culture plate, and incubated overnight. Krebs solution containing 2 mM glucose was added, incubated for 10 min, and the supernatant was collected by centrifugation. After washing the cells with sugar-free Krebs, the cells were resuspended in Krebs solution containing 20 mM glucose, incubated for 10 min, and the supernatant was collected by centrifugation. According to the standard protocol, the C-peptide level in the supernatant sample was analyzed using a mouse C-peptide ELISA kit (mlbio, ml-1015542). Results: Isoastragaloside I can effectively promote the differentiation of mPDOs into functional β cells in vitro. Flow cytometry showed that the proportion of C-peptide+ cells in the differentiated mPDOs was approximately 40% ( Figure 5 AB), which increased the differentiation efficiency by nearly 30 times compared with the results reported in the literature, and was able to secrete C-peptide ( Figure 5 C), Physiological response to glucose stimulation with mature β cells.

[0109] 2. Cultivation of Human Biliary Organoids

[0110] Human extrahepatic cholangiocytes were initially seeded in extracellular matrix and cultured in hEM medium at 37°C, 5% CO2 incubator for 5 days to form organoids.

[0111] (1) Primary culture of human extrahepatic bile duct organoid (hBDOs): Use a mechanical method to directly dissect the human bile tree duct (BD) under a dissecting microscope, place the obtained BD in an EP tube containing collagenase IV, and cut it into pieces using surgical scissors. Digest at 37°C for 20 minutes, take out every 5 minutes, and repeatedly blow with a 1mL pipette tip to terminate the digestion on ice. Centrifuge and discard the supernatant, wash three times with sterile PBS, resuspend the digested cells in Matrigel (Corning, 54234), drop them into a 24-well plate and let stand at 37°C for 5 minutes to allow the matrix gel to solidify. Add 800μL of proliferation medium (human expansion medium, hEM) to each well for culture. For specific operation steps, see Figure 6 A.

[0112] The cells obtained by the above method are cultured in Matrigel and proliferate for about 72 hours to form a distinct closed structure. Within 2 weeks, they proliferate in large quantities to form a cystic organoid with a significant morphology. When the cells grow to fill the Matrigel, they can be subcultured and cryopreserved.

[0113] (2) Subculture of human extrahepatic bile duct organoids (hBDOs): Use pre-cooled high-glucose DMEM medium (HyClone; SH30022.01) to break up the organoids and resuspend them. After centrifugation, remove the supernatant, and use Matrigel and hEM to subculture the precipitate. Depending on the cell density, subculture once every 7 to 8 days at a ratio of 1:3-1:5.

[0114] (3) Cryopreservation of human extrahepatic bile duct organoids (hBDOs): Use pre-cooled high-glucose DMEM medium (HyClone; SH30022.01) to break up the organoids and resuspend them. After centrifugation to remove the supernatant, add 1 mL of pre-cooled organoid freezing solution and transfer the resuspended organoids into cell cryopreservation tubes. After placing the cryopreservation tubes in a cryopreservation box, move them into a -80°C refrigerator overnight. The next day, transfer the cryopreservation tubes into liquid nitrogen for storage.

[0115] The hBDOs obtained in this study can be passaged for a long time and have stable proliferation and passage ability. Even when passaged to the 20th generation, they can still maintain a good cell state. Figure 6 B. The structural formula of isoastragaloside I is shown in Figure 3 As shown in A.

[0116] The human monotubular epithelial cells were cultured in EM culture medium containing any one or more of astragaloside I-VIII, isoastragaloside I, II and IV, acetylastragaloside, cyclosieversioside E, F and G, agroastragaloside I-IV and soybean saponin I at final concentrations of 0.1, 0.5, 1, 2, 4, and 8 μM, respectively, and any one or more of their derivatives. The induction time was 14 days, and finally pancreatic islet cells were obtained.

[0117] The following experiments are used to verify the experimental results:

[0118] (1) In vivo transplantation experiment: Nu / Nu mice were intraperitoneally injected with streptozotocin (160 mg / kg) 7 days before transplantation to induce diabetes. Non-fasting blood glucose in the tail vein samples was measured with a blood glucose meter, and mice with blood glucose levels above 16.8 mM were selected as diabetic model mice. hBDOs treated with isoastragaloside I for 7 days were broken into single cells with pancreatic enzymes and then heated for 10 min. 6Cells / islet were transplanted into the renal capsule of recipient mice, and routine nonfasting blood glucose was measured every 7 days after transplantation. At 8 weeks after transplantation, nephrectomy was performed to examine the effect of removing the transplanted organoids or islets on glycemic improvement.

[0119] (2) Glucose tolerance test: The glucose tolerance test was performed according to the standard protocol. Mice were starved overnight and intraperitoneally injected with 1 g / kg of glucose. Blood glucose levels were measured at 0, 15, 30, 60, 90, and 120 min. Serum was collected before and after glucose injection, and changes in insulin content were determined by ELISA.

[0120] Results: hBDOs differentiated by 1 μM isoastragaloside I were transplanted into the renal cysts of STZ-induced diabetic mice, and it was observed that the blood glucose level of the mice decreased significantly ( Figure 7 A), Glucose tolerance test showed that the glucose tolerance of hBDOs transplanted mice was improved compared with the control group ( Figure 7 BC), and the serum insulin level increased ( Figure 7 D). After the transplanted kidney was removed, the blood glucose level of mice increased significantly ( Figure 7 A), further proving that the decrease in blood sugar was indeed caused by the transplanted hBDOs.

[0121] Example 3. Application of pancreatic β cells

[0122] The cells can be used to prepare artificial pancreatic islet systems and methods for in vivo application to treat diabetes:

[0123] The pancreatic β cells obtained in Example 2 are mixed with a pharmaceutical carrier including an extracellular matrix, nanomaterials or microfluids, and implanted into an animal, or the pancreatic β cells are mixed with sodium chloride, magnesium chloride, sodium calcium ethylenediaminetetraacetate and water for injection to support the injection, and implanted into an animal for treatment. The specific steps are as follows:

[0124] Nu / Nu mice were intraperitoneally injected with streptozotocin (160 mg / kg) 7 days before transplantation to induce diabetes. Non-fasting blood glucose in the tail vein samples was measured with a blood glucose meter, and mice with blood glucose levels above 16.8 mM were selected as diabetic model mice. hBDOs treated with isoastragaloside I for 7 days were broken into single cells with pancreatic enzymes and then heated for 10 min. 6 Cells / cells were transplanted into the renal capsule of recipient mice, and routine non-fasting blood glucose was measured every 7 days after transplantation. Glucose tolerance test was performed according to the standard protocol. Mice were starved overnight and intraperitoneally injected with 1g / kg of glucose. Blood glucose levels were detected at 0, 15, 30, 60, 90 and 120min. Serum was collected before and after glucose injection and measured by ELISA. At the 8th week of transplantation, nephrectomy was performed to examine the effect of removing the transplanted organoids or islets on the improvement of blood glucose.

[0125] Results: Under two-dimensional or three-dimensional culture conditions, isoastragaloside I can promote the formation of pancreatic islet-like cells by PDX1-positive cells in the hepatobiliary pancreatic gastrointestinal epithelium. Transplantation into diabetic animals can effectively reduce blood sugar, improve glucose tolerance, and treat diabetes. This method can avoid the binding of hydrogels formed by immune-rejecting peptides and their derivatives, thereby reducing immune rejection.

[0126] Example 4. An inducing agent for inducing ductal cell differentiation

[0127] Human expansion medium (hEM) formula: 1% Penicillin-Streptomycin Solution (HyClone; SV30010), 1% glutamine supplement (gibco; 35050-061), 2% B27 without vitamin A (Thermo; 12587010), 50ng / mL EGF (MCE; HY-P7067), 50ng / mL FGF10 (PeproTech; 100-26-25), 25ng / mL NOGGIN (PeproTech; 120-10C-20), 1% N2 (Thermo; 17502001), 10nM Gastrin (SIGMA; G9145), 3μM PGE2 (SIGMA; P0409), 5μM A83-01 (MCE; HY-10432), 1mol / L Nicotinamide (Sigma; N0636), 1 mol / L N-acetyl-L-cysteine ​​(Sigma; A9165), 100 ng / mL R-Spondin-1 (R&D; 7150-RS), add D / F12 to 40 mL (HyClone; SH30022.01);

[0128] Mouse expansion medium (mEM) formula: 1% Penicillin-Streptomycin Solution (HyClone; SV30010), 1% glutamine supplement (gibco; 35050-061), 2% B27 without vitamin A (Thermo; 12587010), 50ng / mL EGF (MCE; HY-P7067), 50ng / mL FGF10 (PeproTech; 100-26-25), 25ng / mL NOGGIN (PeproTech; 120-10C-20), 1mol / L Nicotinamide (Sigma; N0636), 1mol / L N-acetyl-L-cysteine ​​(Sigma; A9165), 100ng / mL R-Spondin-1 (R&D; 7150-RS), supplemented with D / F12 to 40 mL (HyClone; SH30022.01); astragalosides IV, astragalosidone I, astragalosidone II, astragaloside I, isoastragalosidone II or isoastragalosidone I were prepared in the above EM medium with a final concentration of 0.5, 1, 2, 4, 8 μM.

[0129] Example 5. A method for inducing ductal cells to differentiate into pancreatic islet cells

[0130] Ductal organoid culture stage (stage I) and induction differentiation into pancreatic islet cells stage (stage II).

[0131] (1) Phase I includes the following steps: (a) mechanically peeling off the cells under a dissecting microscope, obtaining intrahepatic bile duct epithelial cells, extrahepatic bile duct epithelial cells or pancreatic duct epithelial cells by enzymatic digestion, and embedding them in matrix gel; (b) amplifying the cells in expansion medium (EM). When the cells grow to fill the matrix gel, they can be passaged (about 10-14 days), and then passaged every 7-8 days.

[0132] Small molecules added to the proliferation medium in phase I include B27 (B-27 supplement without vitamin A), EGF (epidermal growth factor), FGF10 (fibroblast growth factor 10), NOGGIN (Noggin protein), N2 (Thermo; 17502001), Gastrin (SIGMA; G9145), PGE2 (SIGMA; P0409), A83-01 (MCE; HY-10432), Nicotinamide, N-acetyl-L-cysteine, and R-spondin 1.

[0133] (2) Phase II includes: adding 1 μM concentration of astragaloside to the EM culture medium of EPOs and culturing for 14 days.

[0134] The astragaloside extract added in stage II includes any one or more of astragaloside I to VIII, isoastragaloside I, II and IV, acetylastragaloside, cyclosieversioside E, F and G, agroastragaloside I to IV and soybean saponin I, as well as any one or more of their derivatives.

[0135] Results: Astragaloside functionally induced pancreatic endocrine cells, mainly including β cells. In the embodiment, the induced pancreatic endocrine cells express at least one cell marker: β cell marker insulin (Insulin; INS), α cell marker glucagon (Glucagon; GCG), δ cell marker somatostatin (Somatostatin; SST), pp cell marker pancreatic polypeptide (panoreatio polypeptide; PP). At the same time Figure 5 The flow cytometry results show that the differentiation efficiency of astragalus saponins of the present invention can reach 45%, which is nearly 30 times higher than the 1.5% differentiation efficiency previously recorded in the literature [Loomans C, Giuliani NW, Balak J, et al. Expansion of Adult Human Pancreatic Tissue Yields Organoids Harboring Progenitor Cells with Endocrine Differentiation Potential [J]. Stem Cell Reports, 2018, 10 (3): 712.]. SEQUENCE LISTING <110> Northeast Forestry University <120> A pancreatic islet cell inducer, culture medium, method for obtaining pancreatic beta cells and application thereof <160> 14 <170> PatentIn version 3.5 <210> 1 <211> twenty two <212> DNA <213> Synthesis <400> 1 ccctaagtga tccgctacaa tc 22 <210> 2 <211> 19 <212> DNA <213> Synthesis <400> 2 cttgacaaaa gcctgggtg 19 <210> 3 <211> twenty one <212> DNA <213> Synthesis <400> 3 cggatgacgc caaacttaca a 21 <210> 4 <211> 20 <212> DNA <213> Synthesis <400> 4 tttccactag cacccaccac 20 <210> 5 <211> twenty four <212> DNA <213> Synthesis <400> 5 ccatttactt tgtggctgga ttgc 24 <210> 6 <211> twenty two <212> DNA <213> Synthesis <400> 6 atgtgccctg tgagtggcgt tt 22 <210> 7 <211> twenty three <212> DNA <213> Synthesis <400> 7 gacacctgag cagatggcac aat 23 <210> 8 <211> 20 <212> DNA <213> Synthesis <400> 8 ccacgggctg aagacaagag 20 <210> 9 <211> twenty two <212> DNA <213> Synthesis <400> 9 tctggaagac attcacatcc tg 22 <210> 10 <211> twenty two <212> DNA <213> Synthesis <400> 10 tctaatgcag ggtcaagttg ag 22 <210> 11 <211> twenty two <212> DNA <213> Synthesis <400> 11 ggagtagcag ggttcagact tg 22 <210> 12 <211> twenty three <212> DNA <213> Synthesis <400> 12 actaccttta attgcctcac cac 23 <210> 13 <211> 28 <212> DNA <213> Synthesis <400> 13 cacggcaaat tcaacggcac agtcaagg 28 <210> 14 <211> twenty three <212> DNA <213> Synthesis <400> 14 gttcacaccc atcacaaaca tgg 23

Claims

1. Use of astragaloside as an inducer of pancreatic islet cells in obtaining pancreatic β cells in vitro, characterized in that: The astragaloside is isoastragaloside I; the concentration of the astragaloside is 0.1-8 μM.

2. A method for obtaining pancreatic β cells, characterized in that: Epithelial cells are cultured in a culture medium containing astragaloside to differentiate and obtain pancreatic β cells; the epithelial cells are liver, gallbladder, pancreas, stomach and intestinal epithelial cells of humans or mammals; the astragaloside is isoastragaloside I; the concentration of the astragaloside is 0.1-8 μM.